Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial

IMPORTANCE: Deficient mismatch mutation repair mechanisms may sensitize endometrial cancers to anti–programmed death 1 (PD-1) therapies. Dostarlimab (TSR-042) is an investigational anti–PD-1 antibody that binds with high affinity to the PD-1 receptor. OBJECTIVE: To assess the antitumor activity and...

Descripción completa

Detalles Bibliográficos
Autores principales: Oaknin, Ana, Tinker, Anna V., Gilbert, Lucy, Samouëlian, Vanessa, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, Sabatier, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530821/
https://www.ncbi.nlm.nih.gov/pubmed/33001143
http://dx.doi.org/10.1001/jamaoncol.2020.4515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530821/
https://www.ncbi.nlm.nih.gov/pubmed/33001143
http://dx.doi.org/10.1001/jamaoncol.2020.4515

Ejemplares similares